Table 3.
Newborn Outcomes
| Methadone (N=248) |
Buprenorphine (N=361) |
P | |||
|---|---|---|---|---|---|
| Infant Characteristics | N | m (sd) or n (%) | N | m (sd) or n (%) | |
| Male | 248 | 111 (45%) | 361 | 177 (49%) | .299 |
| EGA at delivery (wks) | 248 | 38.2 (2.5) | 361 | 39.2 (2.2) | <.001 |
| Preterm (EGA<37 wks) | 248 | 43 (17%) | 361 | 36 (10%) | <.001 |
| Birth weight (grams) | 248 | 2899.7 (583.1) | 361 | 3143.3 (578.9) | <.001 |
| Standardized (z-score) | 248 | −0.59 (.93) | 361 | −0.46 (.98) | .089 |
| < 5th percentile | 248 | 32 (13%) | 361 | 40 (11%) | .494 |
| Head circumference (cm) | 209 | 33.0 (2.0) | 279 | 33.6 (2.1) | <.001 |
| Standardized (z-score) | 209 | −0.50 (.80) | 279 | −0.46 (.98) | .669 |
| Infants treated for NAS | 245 | 106 (42%) | 358 | 82 (23%) | <0.001 |
| Duration of treatment for NAS (days) | 106 | 133±83 | 79 | 83±60 | <0.001 |
| Length of stay, EGA ≥ 37 wks, (days) | 205 | 5.6 (2.8) | 325 | 4.2 (12.6) | .107 |
| Breast milk at discharge | 247 | 156 (63%) | 358 | 267 (75%) | .003 |
| Discharged in care of mother/family | 248 | 237 (96%) | 360 | 351 (98%) | .189 |
EGA, Estimated gestational age; m, Mean; sd, Standard Deviation; NAS, Neonatal abstinence syndrome